MARSHALL WACE, LLP

Position in ERAS — Erasca, Inc.

CIK 1318757 LONDON, X0

Position in ERAS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$6,901,190

+$6,670,699 QoQ

Shares Held

426,526

+588.4% QoQ

Ownership

0.137%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2022

12 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,764,425,276 across 279 Biotechnology names. ERAS ranks #82 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$6,901,190	426,526	+588.4%	Shares	Other	2026-05-15
2025-12-31	$230,491	61,960	-88.2%	Shares	Other	2026-02-13
2025-09-30	$1,146,699	526,009	-74.6%	Shares	Other	2025-11-13
2025-06-30	$2,634,519	2,074,425	+2.3%	Shares	Other	2025-08-13
2025-03-31	$2,777,026	2,027,027	0.0%	Shares	Other	2025-05-15
2024-12-31	$5,087,837	2,027,027	-33.1%	Shares	Other	2025-02-13
2024-09-30	$8,265,694	3,027,727	-17.6%	Shares	Other	2024-11-14
2024-06-30	$8,666,804	3,672,375	+485.4%	Shares	Other	2024-08-14
2023-12-31	$1,336,154	627,303	-13.4%	Shares	Other	2024-02-14
2023-03-31	$2,179,408	724,056	+163.7%	Shares	Other	2023-05-15
2022-12-31	$1,183,250	274,536	+2308.0%	Shares	Other	2023-02-14
2022-03-31	$98,048	11,401	—	Shares	Other	2022-05-16
No filing history on record for this holder in this stock.